Tag: SENS401
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved – 03/11/2024 at 07:30
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved•The presence of SENS-401 is confirmed in the…
Sensorion publishes positive efficacy data in the SENS-401 phase 2a clinical study – 07/05/2023 at 07:30
Positive preliminary data shows that SENS-401 has a clinically significant effecton preservation of residual hearing after cochlear implantation in all patientsadults treated so far.• On June 19, Sensorion announced the…
Sensorion publishes promising preliminary data from the Phase 2a clinical study of Sens-401 – 06/19/2023 at 09:03
(AOF) – Sensorion, a pioneering clinical-stage biotechnology company dedicated to developing innovative therapies to restore, treat and prevent hearing loss, announces promising preliminary results from its Phase 1 proof-of-concept (POC)…
Sensorion: first patient in SENS-401 Phase 2a proof-of-concept trial in cisplatin-induced ototoxicity
Through Arnaud Bives Published on 03/01/2023 at 07:41 (Boursier.com) — Sensorion enrolled the first patient in its Phase 2a proof-of-concept clinical trial…